Genmab A/S (NASDAQ:GMAB) Shares Gap Up – Here’s Why

Genmab A/S (NASDAQ:GMAB)’s share price gapped up prior to trading on Thursday . The stock had previously closed at $20.23, but opened at $20.93. Genmab A/S shares last traded at $20.84, with a volume of 112,594 shares trading hands.

Analyst Ratings Changes

A number of equities analysts have issued reports on GMAB shares. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research report on Wednesday, January 8th. BMO Capital Markets reiterated an “outperform” rating and set a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Finally, Redburn Atlantic started coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Stock Down 2.0 %

The firm has a market capitalization of $13.76 billion, a PE ratio of 20.19, a price-to-earnings-growth ratio of 0.59 and a beta of 0.97. The business has a 50-day moving average price of $21.15 and a 200-day moving average price of $24.07.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The firm had revenue of $816.10 million for the quarter, compared to analysts’ expectations of $838.20 million. During the same period in the previous year, the firm posted $0.47 EPS. On average, equities research analysts anticipate that Genmab A/S will post 1.28 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of GMAB. Rhumbline Advisers raised its stake in shares of Genmab A/S by 7.1% in the 2nd quarter. Rhumbline Advisers now owns 18,694 shares of the company’s stock valued at $470,000 after acquiring an additional 1,236 shares during the period. Benjamin F. Edwards & Company Inc. raised its holdings in shares of Genmab A/S by 7.1% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after buying an additional 478 shares during the period. Cubist Systematic Strategies LLC lifted its stake in Genmab A/S by 109.7% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock worth $7,000,000 after acquiring an additional 145,689 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in Genmab A/S during the 2nd quarter valued at about $457,000. Finally, Sanctuary Advisors LLC acquired a new position in Genmab A/S in the 2nd quarter valued at about $1,354,000. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.